Britain Urged to Develop Vaccine Manufacturing Infrastructure as Essential Pandemic Preparedness
Former Health Secretary Matt Hancock advocates for domestic vaccine production capability after Covid-19 exposed international supply vulnerabilities.
The United Kingdom must prioritize establishing its own vaccine manufacturing capability as a crucial component of preparing for future pandemics, according to Matt Hancock, the country’s former health secretary.
Speaking at the Covid-19 public inquiry, Hancock emphasized the necessity for a sovereign, domestic production facility to ensure timely vaccine availability upon regulatory approval.
Hancock, who played a pivotal role in managing Britain’s response to the Covid-19 crisis, underscored that while the UK’s vaccine research is commendable, its manufacturing infrastructure lacks the capacity to produce the required doses at a large scale.
His testimony, provided under questioning by Hugo Keith KC, highlighted a previous assumption within the UK that the geographical location of vaccine manufacturing and the fill and finish processes was inconsequential in peacetime contexts.
However, the pandemic illustrated that this assumption was flawed due to the intense global demand for vaccines once they receive regulatory clearance.
“The moment a vaccine gets signed off, there’s going to be enormous demand, and geopolitical-level demand for this, therefore having that manufacture and fill and finish onshore, physically within the UK, is critical in the way that it simply isn’t in normal times,” Hancock stated.
Addressing issues that arose during the pandemic, Hancock criticized the European Union’s approach to vaccine distribution, referencing the dispute between the UK and Brussels over the allocation of the Oxford/AstraZeneca Covid-19 vaccine.
Despite being cautioned by Keith that UK-EU relations were beyond the scope of the inquiry, Hancock insisted that understanding these challenges is essential to avoid future pitfalls.
“A whole load of our vaccines were still manufactured on the European continent and that caused us significant problems,” he added.
The Covid inquiry, led by Heather Hallett, is currently examining vaccines and therapeutics, acknowledging them as rare successes in the UK’s broader crisis management, particularly through the development of the Oxford/AstraZeneca vaccine and the discovery of dexamethasone’s life-saving potential.
Despite being the first nation to implement a Covid-19 vaccine rollout, the inquiry revealed that various communities, including ethnic minorities, disabled individuals, clinically vulnerable groups, migrants, and Travellers, encountered significant barriers in accessing vaccines, antivirals, and other treatments.
Challenges included limited access to information and guidance in multiple languages, as well as instances of discrimination and skepticism towards vaccine safety.
Complementing the inquiry's findings, Pat McFadden, the chancellor of the duchy of Lancaster, announced plans for a national pandemic-preparedness exercise.
Aimed at testing the UK's readiness for future global health crises, this extensive exercise, recommended by the Covid inquiry, will involve thousands across the UK, scheduled to take place over several days in the coming autumn.
Speaking at the Covid-19 public inquiry, Hancock emphasized the necessity for a sovereign, domestic production facility to ensure timely vaccine availability upon regulatory approval.
Hancock, who played a pivotal role in managing Britain’s response to the Covid-19 crisis, underscored that while the UK’s vaccine research is commendable, its manufacturing infrastructure lacks the capacity to produce the required doses at a large scale.
His testimony, provided under questioning by Hugo Keith KC, highlighted a previous assumption within the UK that the geographical location of vaccine manufacturing and the fill and finish processes was inconsequential in peacetime contexts.
However, the pandemic illustrated that this assumption was flawed due to the intense global demand for vaccines once they receive regulatory clearance.
“The moment a vaccine gets signed off, there’s going to be enormous demand, and geopolitical-level demand for this, therefore having that manufacture and fill and finish onshore, physically within the UK, is critical in the way that it simply isn’t in normal times,” Hancock stated.
Addressing issues that arose during the pandemic, Hancock criticized the European Union’s approach to vaccine distribution, referencing the dispute between the UK and Brussels over the allocation of the Oxford/AstraZeneca Covid-19 vaccine.
Despite being cautioned by Keith that UK-EU relations were beyond the scope of the inquiry, Hancock insisted that understanding these challenges is essential to avoid future pitfalls.
“A whole load of our vaccines were still manufactured on the European continent and that caused us significant problems,” he added.
The Covid inquiry, led by Heather Hallett, is currently examining vaccines and therapeutics, acknowledging them as rare successes in the UK’s broader crisis management, particularly through the development of the Oxford/AstraZeneca vaccine and the discovery of dexamethasone’s life-saving potential.
Despite being the first nation to implement a Covid-19 vaccine rollout, the inquiry revealed that various communities, including ethnic minorities, disabled individuals, clinically vulnerable groups, migrants, and Travellers, encountered significant barriers in accessing vaccines, antivirals, and other treatments.
Challenges included limited access to information and guidance in multiple languages, as well as instances of discrimination and skepticism towards vaccine safety.
Complementing the inquiry's findings, Pat McFadden, the chancellor of the duchy of Lancaster, announced plans for a national pandemic-preparedness exercise.
Aimed at testing the UK's readiness for future global health crises, this extensive exercise, recommended by the Covid inquiry, will involve thousands across the UK, scheduled to take place over several days in the coming autumn.